VEGF inhibitor monoclonal antibody / Bevacizumab biosimilar

This page covers all VEGF inhibitor monoclonal antibody / Bevacizumab biosimilar drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting VEGF (Vascular Endothelial Growth Factor).

Targets

VEGF (Vascular Endothelial Growth Factor)

Marketed (1)

• Bevacizumab-awwb · Amgen · Oncology
  Bevacizumab-awwb is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells.

Phase 3 pipeline (2)

• Gentuximab Injection · Changchun GeneScience Pharmaceutical Co., Ltd. · Oncology
  Gentuximab is a monoclonal antibody that targets and inhibits vascular endothelial growth factor (VEGF) to suppress tumor angiogenesis and blood vessel formation.
• QL1101 · Qilu Pharmaceutical Co., Ltd. · Oncology
  QL1101 is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.

Patent intelligence

• vegf inhibitor monoclonal antibody patent landscape — aggregated cliff calendar, attackable patents, originator estates